EP0146455A2 - Derivate von Dextran mit antikoagulierenden und antikomplementären Eigenschaften, ihre Herstellung und ihre biologischen Anwendungen - Google Patents
Derivate von Dextran mit antikoagulierenden und antikomplementären Eigenschaften, ihre Herstellung und ihre biologischen Anwendungen Download PDFInfo
- Publication number
- EP0146455A2 EP0146455A2 EP84402466A EP84402466A EP0146455A2 EP 0146455 A2 EP0146455 A2 EP 0146455A2 EP 84402466 A EP84402466 A EP 84402466A EP 84402466 A EP84402466 A EP 84402466A EP 0146455 A2 EP0146455 A2 EP 0146455A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- units
- dextran
- group
- derivatives
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0021—Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
Definitions
- the invention relates to dextran derivatives endowed, in particular, with anticoagulant and anticomplementary properties, with their preparation and with their biological applications.
- heparin is widely used as an antithrombotic drug due to its high anticoagulant properties.
- Dextran is a polyglucoside with a molecular weight of approximately 5000 to several million daltons, formed of glucosyl A units, linked by essentially 1-6 sequences, of formula:
- dextrans of molecular weight generally less than about 100,000 are used.
- This product is used, in particular, as a substitute for blood plasma or at least as a plasma expander or volume restorer. These uses may, however, in some cases lead to immune shock.
- the invention therefore aims to provide dextran derivatives having at least some of the biological properties of heparin and usable as biomaterials thanks to their high tolerance.
- B and ( 2 ) of substitution chains, on the D units, comprising aryl groups substituted by an anion of an inorganic or organic salt and more especially arylsulfonate groups and linked to the dextran chain by an arm comprising an amide group .
- the dextran derivatives also contain units C substituted by radicals of structure -O- (CH) -CO-NH- R 1 in which R 1 and n are as defined above.
- a preferred family of dextran derivatives according to the invention comprises B units substituted by a chain -O-CH 2 -COO - .
- the units B are substituted by carboxyethyl, carboxypropyl or carboxybutyl groups -O- (CH 2 ) n -COO, n being respectively equal to 2.3 or 4.
- the units B are substituted by groups -O- (CH 2 ) n -CO-NH- (CH 2 ) n , -COO.
- n 'is equal to 4.5 or 7 comprise a radical -NH- (CH 2 ) n' -COO corresponding respectively to a valeric acid, aminocaproic acid and aminocaprylic acid group.
- a preferred group of dextran derivatives of the invention contains, at the same time as the units B of one of the families defined above, units D substituted by a chain of structure -O- (CH 2 ) n -
- the dextran chains contain, in addition to the units B above, units D substituted by a chain of structure -O- (CH 2 ) n -CO-NH-CH 2 .
- the D units are substituted by a chain of structure -0- (CH) -CO-
- R 2 is as defined above and advantageously represents a group -SO 3 and n is a number from 1 to 4, preferably equal to 1.
- substitutions of units B, C, and D essentially occupy position 2 of the basic glucosyl unit.
- the derivatives in which these substitutions occupy other positions as well as possibly position 2 fall within the scope of the invention.
- the invention also relates to the derivatives in which a part of the -OH groups of the glucosyls are in the form -OR 2 .
- the inventors By preparing a whole range of derivatives, the inventors have been able to demonstrate that the anticoagulant activity becomes very weak when the level of the B units is less than approximately 35%. It is the same in the total absence of D reasons.
- Derivatives of this type containing approximately 9-12% of D units, preferably up to approximately 20%, thus exhibit an antithrombic activity which can reach values of the order of 300 to 400 ⁇ T / mg.
- Advantageous corresponding products have high molecular weights greater than 40,000 and even approximately 60 or 80,000. In these products, the level of C units may be zero.
- the antithrombic activity is lower by around 1 to 5uT / mg and the anticomplementary activity always higher by around 1 to 10 ⁇ g / 10 7 EAC 4b3bBbP in derivatives with a lower percentage of D d motifs '' about 4%, the rate of B motifs being 40 to 50%. In these derivatives, the molecular weight is lower, around 10,000.
- the antithrombic and anticomplementary activities are measured according to the methods reported in the examples.
- a particularly preferred category of derivatives of the invention comprises the dextran derivatives comprising the following units A, B, C, and D according to the proportions given above.
- the invention also relates to a process for the preparation of the dextran derivatives defined above.
- a dextran chain formed of unsubstituted units A is used and the units B, C and D are produced successively, these units each being obtained from that previously prepared in the order indicated.
- the separation of dextrans can be carried out first, followed by the steps mentioned above.
- a reactive derivative such as a halide is advantageously reacted with dextran, more especially for reasons of availability, a chloride.
- the glucosylation reaction is carried out in basic medium under conditions which make it possible to avoid degradation of the dextran chain sensitive to hydrolysis.
- the basic reaction mixture containing the dextran is brought to a temperature of the order of 0 ° C, or lower, in particular from -4 ° C to + 5 ° C.
- the mixture After adding the reactive derivative, the mixture is brought to a temperature above ambient, which can reach approximately 70 ° C.
- the temperature setting allows the substitution efficiency to be varied practically at will. It is so it is possible to obtain carboxyl levels of 40 to 60% as well as levels reaching 80% in one step and practically 100% in two steps and even exceeding them.
- This modulation is of interest since when it is desired to have products with high anticoagulant properties, it is preferable to have a higher rate of D units, while this rate must be higher to increase the anticomplementary activity. drifts.
- the ratio of the concentration of reactive derivative to that of dextran is advantageously from 1 to approximately 3.5.
- the pH is lowered to a neutral pH.
- the products are precipitated using a solvent, in particular an alcoholic solvent such as methanol.
- the chain R in the units B represents a group -CO-NH- (CH 2 ) n
- the products are advantageously obtained from the units B substituted by a chain -0- (CH 2 ) n -COO - by reaction with the corresponding amino acids.
- the step for developing the patterns C comprises the coupling of the derivatives of formula NH 2 - R 1 with the substitution chain of the units B.
- a coupling agent is advantageously used in an acid medium, at room temperature.
- the mixed anhydride of dextran is prepared by reacting an alkyl chloroformate (in particular ethyl or isobutyl) and a derivative capable of forming a hydrochloride with the liberated hydrochloric acid such as triethylamine, N-methylmorpholine or the like.
- This activation step is preferably carried out at a temperature below 0 ° C and even from -15 ° C approximately. This reaction takes place very quickly in a few minutes and then the coupling is carried out at low temperature.
- the ratio of the concentration of derivative to be coupled to that of the substituted dextran is advantageously of the order of 2 and that of chloroformate relative to the dextran approximately of 1.
- dextran chains formed containing B units are then reacted with a reactive derivative containing R 2 and making it possible to fix R 2 on the aryl nucleus of the chains of B.
- substitution with SO 3 - groups is advantageously carried out using chlorosulfonic acid, under dilute conditions in order to avoid degradation of the dextran chain. This step is carried out in a heterogeneous phase and the product is recovered washed and dried.
- the substituted dextran thus obtained is washed and then stored in lyophilized form.
- the biological activity of the dextran derivatives defined above has been studied at various levels, in particular on certain coagulation proteins, in particular, thrombin, and on the complement system.
- mice of approximately 20 g by intravenous injection of 0.5 ml per mouse, of a solution of 40 mg / ml of the modified dextran according to the present invention in isotonic NaCl solute. These tests have demonstrated the total safety of the products in accordance with the present invention: no reaction, neither during the injection nor for 14 days following the injection, has been observed.
- these derivatives are particularly suitable for use as substitutes for blood plasma more especially as expanders with the advantage compared to dextrans. reduce the risk of hypersensitivity observed in certain cases.
- the invention therefore also relates to biomaterials which can be used as blood plasma substitutes and expanders based on the above dextran derivatives, in solution of approximately 5 to 15%, in particular approximately 10% in a saline medium. These expanders are used, for example, at a rate of approximately 1.5 to 2 1 / day.
- the dextran derivatives of the invention in particular those of high molecular weight, greater than approximately 40,000, have an antithrombic activity a of the order of 300 to 400 u T / mg or more.
- Such products advantageously comprise from 40 to 50% of B units approximately and 9-12% and even up to approximately 20% of C units.
- Preferred products have a molecular weight greater than 60,000 and even to 80,000.
- the invention therefore relates to pharmaceutical compositions comprising the dextran derivatives of the invention and more especially compositions exhibiting anticoagulant activity comprising, as active principle, an effective amount of at least one derivative as defined above with the preferred proportions indicated.
- a preferred composition contains the dextran derivatives of Example 1, advantageously in the above proportions for the units B and D, the content of C possibly being zero.
- compositions contain a pharmaceutical vehicle suitable for administration by the oral, rectal, ointment or injectable route.
- Solutions for injection contain 10 to 50 mg of dextran per dose.
- the injection can be given subcutaneously, intravenously or by infusion and repeated 2 to 3 times a day depending on the patient's condition and the results of biological tests, as performed in the usual heparin treatments.
- the derivatives of the invention also constitute synthetic intermediates for the development of drug vectors. They are, in fact, usable as a support for conveying active substances of various types.
- the temperature is brought to 70 ° C. and maintained at this temperature and with stirring for 20 minutes.
- the pH which has a value close to 11, is adjusted to 7 by addition of acetic acid.
- the product is precipitated using 3 liters of methanol, then washed with methanol and dried in an oven under vacuum at approximately 40 ° C.
- the pH is adjusted to about 3.5 with 1N hydrochloric acid.
- EEDQ N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline
- the product obtained at the end of the 3rd stage is dissolved in an aqueous sodium hydroxide solution and the pH is maintained at 8 for 2 hours.
- the system is then heated to 55 ° C after 20 minutes.
- reaction is thus maintained for a variable time t 2 (from 0 to 60 minutes) depending on the degree of desired substitution (25% to 85% carboxymethyl-dextran).
- the solution is then brought to -15 ° C.
- V 1 (0.44 ml) of N-methylmorpholine and a volume V 2 (0.52 ml) of isobutyl chloroformate are added.
- the reaction is stirred for a time t 1 (5 to 60 min) at -15 ° C, then the temperature is brought to 20 ° C and stirred for 1 hour.
- the product is then drawn under vacuum then precipitated in 500 ml of methanol, filtered on frit then put back in water to be ultrafiltered on a calibrated membrane.
- TT thrombin time
- TR reptilase time
- the thrombin time corresponds to the time of formation of a clot after addition of thrombin to a plasma sample or a fibrinogen solution.
- the reptilase time makes it possible to control that the capacity for transformation of fibrinogen into fibrin is not modified by the presence of the dextran derivative.
- the control time is determined with a volume of buffer free of dextran derivative.
- the heparin used has a USP activity of 173 IU / mg and a molecular weight of 10,700 daltons.
- reptilase times are not lengthened in the presence of polymer and therefore the fibrinogen is not altered. This invariability of reptilase times makes it possible to correlate the prolongation of thrombin times on plasma with an anticoagulant activity.
- the thrombin times on fibrinogen are of the order of that of the controls when the concentrations of dextran derivatives are low.
- the anticoagulant activity (a) is determined from the PPP thrombin times in the presence of various concentrations of polymer.
- Activity a is defined as the number of inactivated thrombin units per milligram of product (uTh / mg).
- This amount of inactivated thrombin is determined from a calibration curve.
- commercial heparin has an activity coefficient a_ equal to 4000 uTh / mg.
- anticoagulant activity a is reported in Table 3 below in uT / mg for the derivatives considered in Table 2. Variation in anticoagulant activity a as a function of the respective proportions of motifs B and D -
- FIG. 2a corresponds to the variation of the activity a of dextran derivatives of starting Mp of 10,500 as a function of the rate of B units with a rate of D units of 15 ⁇ 1 (curve •, of 11 ⁇ 1 (curve ⁇ ) of 6 ⁇ 1 (curve ⁇ ) and 2 ⁇ 1 (curve ⁇
- FIG. 2 b corresponds to the variation of the activity a of dextran derivatives used as a function of the level of D units, the rate of B units being 47.5 1 2.5%.
- the product After passing through this column, the product is divided according to its molecular mass into 5 fractions. (It was verified by chemical dosing that the separation was carried out only according to the mass).
- Proteins in the contact phase are those that activate on contact with a surface other than the endothelium and are responsible, at least in part. activation of other coagulation factors. Kallikrein, an enzyme resulting from the activation of the contact phase, amplifies the activation of this system.
- the revealing activation test in the contact phase consists of measuring the enzymatic activity of kallikrein. This is highlighted by amidolysis of a chromogenic substrate specific for the enzyme (substrate S2302 marketed by Kabj). The speed of release of one of the hydrolysis products, paranitroaniline (pNA) is followed by spectrophotometry at 405 nm.
- substrate S2302 a chromogenic substrate specific for the enzyme
- pNA paranitroaniline
- the increase in optical density per unit of time at 405 nm is proportional to the enzymatic activity of kallikrein.
- the response of this test is global because it does not allow the different stages of activation of the contact phase to be analyzed separately.
- the activation by the dextran derivatives was analyzed according to their concentration and, on the other hand, according to the nature and their composition by substituting.
- the amplitude of the activation of the contact system appears as an increasing function of the concentration of active derivative of dextran.
- the activating power of polymers vis-à-vis the contact phase seems to change depending on the nature and the composition of substituents in a manner analogous to their anticoagulant activity: An increase in activity appears beyond a certain rate of patterns B and seems all the more marked as the rate of patterns D is high.
- the complementary system participates in the mechanisms of recognition or defense of the host vis-à-vis infectious agents or foreign cells.
- the erythrocytes carrying the C3b fragments (small fragment released by the cleavage of C 3 ) and more precisely called EA C4b 3b, are separated from sensitized sheep erythrocytes (EA) according to the protocol described by MD-Kazatchkine et al. J.Cli. Invest. 67, 223.1981.
- the erythrocytes are then placed in the presence of sufficient amounts of protein and stabilizer B, D, P to obtain a “C3 convertase enhancer” site per cell designated by EA C4b 3b Bb P. These sites activate the effector pathway of the complement comprising the plasma proteins C 5 -C 6 -C 7 -C 8 -C 9 and cause hemolysis of erythrocytes which release hemoglobin.
- 0.1 ml fractions of this suspension are removed and added to 0.1 1 ml of DGVB ++ buffer (Veronal buffer + 0.1% gelatin and containing 0.15 mM Ca ++ and 0.5 mM Mg ++ , diluted 1/2 with a 5% dextrose solution containing 0.15 mM Ca ++ and 0.5 mM Mg ++ ) alone or containing adequate amounts of modified dextran according to the present invention .
- DGVB ++ buffer Very buffer + 0.1% gelatin and containing 0.15 mM Ca ++ and 0.5 mM Mg ++ , diluted 1/2 with a 5% dextrose solution containing 0.15 mM Ca ++ and 0.5 mM Mg ++
- the mixture is incubated for 30 minutes at 30 ° C with shaking.
- the C3 convertase sites formed are revealed by an incubation of 60 minutes at 37 ° C. with shaking.
- the reaction is stopped by adding 1.6 ml of 0.15M NaCl.
- the tubes are centrifuged and the intensity of the lysis is determined by reading the supernatants at 412 nm by analysis with a spectrophotometer.
- the number of hemolytic sites per cell is calculated.
- the inhibitory activity of the product tested is expressed as a percentage inhibition of convertase formation by reference to the control tube where the convertase was formed in the absence of modified dextran in accordance with the present invention.
- This activity is expressed in weight of product (at constant volume) necessary for 50% inhibition of convertase formation.
- the inhibitory activity increases at the same time as the increase in the rate of D motifs for a rate of B motifs of 40-50%, the increase in the rate of B motifs beyond this value does not provide improvement. It should also be noted that the evolution as a function of motifs B and D of the anticomplementary activity is very close to that of the anticoagulant activity a.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Materials Engineering (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT84402466T ATE74929T1 (de) | 1983-11-30 | 1984-11-30 | Derivate von dextran mit antikoagulierenden und antikomplementaeren eigenschaften, ihre herstellung und ihre biologischen anwendungen. |
| EP90122614A EP0428182B1 (de) | 1983-11-30 | 1984-11-30 | Derivate von Dextran mit antikoagulierenden und antikomplementären Eigenschaften, ihre Herstellung und ihre biologischen Anwendungen |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8319110 | 1983-11-30 | ||
| FR8319110A FR2555589B1 (fr) | 1983-11-30 | 1983-11-30 | Nouveaux derives du dextrane a activites anticoagulante en anti-inflammatoire, leur procede de preparation et utilisation de ces derives en tant qu'anticoagulants et en tant que substituts du plasma sanguin |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP90122614.2 Division-Into | 1984-11-30 | ||
| EP90122614A Division EP0428182B1 (de) | 1983-11-30 | 1984-11-30 | Derivate von Dextran mit antikoagulierenden und antikomplementären Eigenschaften, ihre Herstellung und ihre biologischen Anwendungen |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| EP0146455A2 true EP0146455A2 (de) | 1985-06-26 |
| EP0146455A3 EP0146455A3 (en) | 1986-03-26 |
| EP0146455B1 EP0146455B1 (de) | 1992-04-15 |
Family
ID=9294687
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP84402466A Expired - Lifetime EP0146455B1 (de) | 1983-11-30 | 1984-11-30 | Derivate von Dextran mit antikoagulierenden und antikomplementären Eigenschaften, ihre Herstellung und ihre biologischen Anwendungen |
| EP90122614A Expired - Lifetime EP0428182B1 (de) | 1983-11-30 | 1984-11-30 | Derivate von Dextran mit antikoagulierenden und antikomplementären Eigenschaften, ihre Herstellung und ihre biologischen Anwendungen |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP90122614A Expired - Lifetime EP0428182B1 (de) | 1983-11-30 | 1984-11-30 | Derivate von Dextran mit antikoagulierenden und antikomplementären Eigenschaften, ihre Herstellung und ihre biologischen Anwendungen |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US4740594A (de) |
| EP (2) | EP0146455B1 (de) |
| JP (1) | JPH0625202B2 (de) |
| AT (2) | ATE110391T1 (de) |
| CA (1) | CA1231334A (de) |
| DE (2) | DE3485658D1 (de) |
| FR (1) | FR2555589B1 (de) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0354836A1 (de) * | 1988-08-10 | 1990-02-14 | Guerbet S.A. | Jodhaltige Polymere mit Skeletten von Dextran, Verfahren zu ihrer Herstellung und ihre Verwendungen als Kontrastmittel |
| FR2651436A1 (fr) * | 1989-09-05 | 1991-03-08 | Sanofi Sa | Compositions pharmaceutiques contenant un derive substitue soluble de dextrane. |
| WO1999029734A1 (fr) * | 1997-12-11 | 1999-06-17 | Solutions | Derives de dextrane, leur procede de preparation et leurs applications comme medicaments a action biologique specifique |
| FR2966248A1 (fr) * | 2010-10-18 | 2012-04-20 | Centre Nat Rech Scient | Procede de fonctionnalisation de surfaces pour la detection d'analytes |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE453394B (sv) * | 1986-07-07 | 1988-02-01 | Pharmacia Ab | Forfarande for framstellning av sulfaterade polysackarider genom anvendning av ett reducerande medel for sulfateringsreaktionen |
| US4994367A (en) * | 1988-10-07 | 1991-02-19 | East Carolina University | Extended shelf life platelet preparations and process for preparing the same |
| US5693625A (en) * | 1989-03-09 | 1997-12-02 | Therapeutiques Substitutives | Method of regenerating cells and tissues using functionalized dextrans |
| FR2657782B1 (fr) * | 1990-02-06 | 1992-05-22 | Therapeutiques Substitutives | Nouvel agent antitumoral derive du dextrane. |
| US5114932A (en) * | 1990-11-30 | 1992-05-19 | Runge Thomas M | Hyperosmolar oxyreplete hemosubstitute |
| US5306711A (en) * | 1992-06-24 | 1994-04-26 | Georgetown University | Organ preservative solution |
| US6458762B1 (en) | 1994-03-28 | 2002-10-01 | Baxter International, Inc. | Therapeutic use of hemoglobin for preserving tissue viability and reducing restenosis |
| FR2718026B1 (fr) * | 1994-03-30 | 1997-01-17 | Paris Val Marne Universite | Médicament et composition pharmaceutique pour le traitement des muscles. |
| FR2781485B1 (fr) | 1998-07-21 | 2003-08-08 | Denis Barritault | Polymeres biocompatibles leur procede de preparation et les compositions les contenant |
| AU3631999A (en) * | 1998-12-04 | 2000-06-26 | Iliya Yakovlevich Ashkinazi | Biologically active carboxymethyldextran n-arylamides |
| US6060461A (en) * | 1999-02-08 | 2000-05-09 | Drake; James Franklin | Topically applied clotting material |
| FR2794976B1 (fr) * | 1999-06-16 | 2004-05-07 | Solutions | Compositions pharmaceutiques a action cicatrisante ou anti-complementaire comprenant un derive de dextrane |
| US6492103B1 (en) | 2000-01-31 | 2002-12-10 | Organ Recovery Systems, Inc. | System for organ and tissue preservation and hypothermic blood substitution |
| FR2807326B1 (fr) * | 2000-04-10 | 2002-08-23 | Therapeutiques Substitutives | Prothese vasculaire impregnee de dextrane reticule et/ou d'un derive fonctionnalise de dextane reticule et son procede de preparation |
| EP1403379A1 (de) * | 2002-09-24 | 2004-03-31 | QIAGEN GmbH | Verbesserte Koamplifikation von Nukleinsäuren |
| EA010945B1 (ru) | 2003-10-28 | 2008-12-30 | Орган Тиссю Реженерасьон Репарасьон Рамплясман - Отр3 | Применение биосовместимого полимера для изготовления медицинского устройства |
| FR2861308A1 (fr) * | 2003-10-28 | 2005-04-29 | Organes Tissus Regeneration Re | Utilisation de polymeres biocompatibles pour la preparation d'une composition pharmaceutique, dermatologique ou cosmetique destinee a la prevention, au soulagement ou au traitement des genes, desagrements et douleurs |
| FR2914305B1 (fr) * | 2007-03-29 | 2009-07-03 | Proteins & Peptides Man | Dextran fonctionnalise par des amino-acides hydrophobes. |
| US20070087061A1 (en) * | 2005-10-14 | 2007-04-19 | Medafor, Incorporated | Method and composition for creating and/or activating a platelet-rich gel by contact with a porous particulate material, for use in wound care, tissue adhesion, or as a matrix for delivery of therapeutic components |
| US20070086958A1 (en) * | 2005-10-14 | 2007-04-19 | Medafor, Incorporated | Formation of medically useful gels comprising microporous particles and methods of use |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2216617A (en) * | 1938-08-31 | 1940-10-01 | Katz Jacob | Surface active anionic compounds of amino alcohols |
| US2989518A (en) * | 1957-05-13 | 1961-06-20 | Ohio Commw Eng Co | Carboxymethyl benzyl dextran |
| FR2484419B1 (fr) * | 1980-06-16 | 1985-10-04 | Meito Sangyo Kk | Derives du dextranne et leurs sels, leur preparation et produits cosmetiques comprenant ces substances |
| SE8103137L (sv) * | 1981-05-19 | 1982-11-20 | Pharmacia Ab | Polymer med kvartera aminogrupper |
-
1983
- 1983-11-30 FR FR8319110A patent/FR2555589B1/fr not_active Expired
-
1984
- 1984-11-30 EP EP84402466A patent/EP0146455B1/de not_active Expired - Lifetime
- 1984-11-30 US US06/676,649 patent/US4740594A/en not_active Expired - Lifetime
- 1984-11-30 EP EP90122614A patent/EP0428182B1/de not_active Expired - Lifetime
- 1984-11-30 AT AT90122614T patent/ATE110391T1/de not_active IP Right Cessation
- 1984-11-30 DE DE8484402466T patent/DE3485658D1/de not_active Expired - Lifetime
- 1984-11-30 CA CA000469125A patent/CA1231334A/fr not_active Expired
- 1984-11-30 DE DE3486341T patent/DE3486341T2/de not_active Expired - Lifetime
- 1984-11-30 JP JP59253964A patent/JPH0625202B2/ja not_active Expired - Fee Related
- 1984-11-30 AT AT84402466T patent/ATE74929T1/de not_active IP Right Cessation
Non-Patent Citations (1)
| Title |
|---|
| BIOMATERIALS, vol. 3, octobre 1982, pages 221-224, Butterworth & Co., Ltd.; M. MAUZAC et al.: "Antithrombic activity of some polysaccharide resins" * |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0354836A1 (de) * | 1988-08-10 | 1990-02-14 | Guerbet S.A. | Jodhaltige Polymere mit Skeletten von Dextran, Verfahren zu ihrer Herstellung und ihre Verwendungen als Kontrastmittel |
| FR2635327A1 (fr) * | 1988-08-10 | 1990-02-16 | Guerbet Sa | Polymeres iodes, a squelette dextrane, leurs procedes de preparation et leurs applications comme produits de contraste |
| WO1990001500A1 (fr) * | 1988-08-10 | 1990-02-22 | Guerbet S.A. | Polymeres iodes a squelette dextrane, leurs procedes de preparation et leurs applications comme produits de contraste |
| US5126440A (en) * | 1988-08-10 | 1992-06-30 | Guerbert S.A. | Iodinated polymers with dextran skeleton, processes for their preparation and their uses as contrast products |
| FR2651436A1 (fr) * | 1989-09-05 | 1991-03-08 | Sanofi Sa | Compositions pharmaceutiques contenant un derive substitue soluble de dextrane. |
| WO1999029734A1 (fr) * | 1997-12-11 | 1999-06-17 | Solutions | Derives de dextrane, leur procede de preparation et leurs applications comme medicaments a action biologique specifique |
| FR2772382A1 (fr) * | 1997-12-11 | 1999-06-18 | Solutions | Derives de dextrane, leur procede de preparation et leurs applications comme medicaments a action biologique specifique |
| FR2966248A1 (fr) * | 2010-10-18 | 2012-04-20 | Centre Nat Rech Scient | Procede de fonctionnalisation de surfaces pour la detection d'analytes |
| WO2012052874A1 (fr) * | 2010-10-18 | 2012-04-26 | Centre National De La Recherche Scientifique | Procede de fonctionnalisation de surfaces pour la detection d'analytes |
| AU2011319626A1 (en) * | 2010-10-18 | 2013-05-23 | Centre National De La Recherche Scientifique | Method for functionalising surfaces for analyte detection |
| US9671397B2 (en) | 2010-10-18 | 2017-06-06 | Centre National De La Recherche Scientifique | Method for functionalizing surfaces for analyte detection |
Also Published As
| Publication number | Publication date |
|---|---|
| US4740594A (en) | 1988-04-26 |
| FR2555589A1 (fr) | 1985-05-31 |
| JPS60135401A (ja) | 1985-07-18 |
| DE3485658D1 (de) | 1992-05-21 |
| DE3486341T2 (de) | 1995-05-04 |
| ATE110391T1 (de) | 1994-09-15 |
| EP0146455B1 (de) | 1992-04-15 |
| FR2555589B1 (fr) | 1986-05-16 |
| JPH0625202B2 (ja) | 1994-04-06 |
| DE3486341D1 (de) | 1994-09-29 |
| EP0428182B1 (de) | 1994-08-24 |
| EP0146455A3 (en) | 1986-03-26 |
| CA1231334A (fr) | 1988-01-12 |
| ATE74929T1 (de) | 1992-05-15 |
| EP0428182A1 (de) | 1991-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0428182B1 (de) | Derivate von Dextran mit antikoagulierenden und antikomplementären Eigenschaften, ihre Herstellung und ihre biologischen Anwendungen | |
| CA2501546C (fr) | Melanges de polysaccharides derives d'heparine, leur preparation et les compositions pharmaceutiques les contenant | |
| EP0040144B1 (de) | Sulfatisierte Polysaccharide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel | |
| EP0403377A1 (de) | Sulfatierte Polysaccharide, Antikoagulierungs- und Antikomplementärmittel, hergestellt aus Fukanen aus braunen Algen, und Verfahren zu deren Herstellung | |
| EP0293539B1 (de) | Verfahren zur Depolymerisierung von Heparin zum Erhalten eines Heparins mit niedrigem Molekulargewicht und einer antithrombotischen Aktivität | |
| EP0116801A1 (de) | Depolymerisiertes und supersulfatiertes Heparin, Verfahren zu dessen Herstellung und dieses enthaltende pharmazeutische Zusammensetzungen | |
| EP0990002B1 (de) | Dextranderivate, verfahren zu deren herstellung und verwendungen als arzneimittel mit spezifischer, biologischer wirkung | |
| EP2121769A1 (de) | Heparine von geringem molekulargewicht mit mindestens einer kovalenten bindung mit biotin oder einem biotin-derivat sowie verfahren zu ihrer herstellung und verwendung | |
| CA2468759C (fr) | Procede de sulfonation de composes comprenant des groupements hydroxyles (oh) libres ou des amines primaires ou secondaires | |
| CA2089853C (fr) | Conjugues polyethyleneglycol-hirudine, leur procede de preparation et leur emploi pour le traitement des thromboses | |
| CA2678166A1 (fr) | Heparines comprenant au moins une liaison covalente avec la biotine ou un derive de la biotine, leur procede de preparation et leur utilisation | |
| FR2675806A1 (fr) | Polysaccharides sulfates, procede de preparation, composition pharmaceutique et utilisation. | |
| EP0344068B1 (de) | N-Polyosyl-Polypeptide | |
| EP0514449B1 (de) | Dextranverbindung als antitumormittel | |
| EP0138632A2 (de) | Komplexe, welche Oligosaccharide enthalten, ihre Herstellung und ihre biologische und biochemische Verwendung | |
| CA1260461A (fr) | Procede de preparation de compositions de mucopolysaccharides dotes d'une activite antithrombotique elevee | |
| WO2005061550A1 (fr) | Derives carboxy-reduits de l'acide hyaluronique, leur preparation, leur application comme medicament et les compositions pharmaceutiques les renfermant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| AK | Designated contracting states |
Designated state(s): AT BE CH DE FR GB IT LI LU NL SE |
|
| PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
| AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): AT BE CH DE FR GB IT LI LU NL SE |
|
| 17P | Request for examination filed |
Effective date: 19860911 |
|
| 17Q | First examination report despatched |
Effective date: 19871026 |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: CHOAY S.A. |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE FR GB IT LI LU NL SE |
|
| REF | Corresponds to: |
Ref document number: 74929 Country of ref document: AT Date of ref document: 19920515 Kind code of ref document: T |
|
| XX | Miscellaneous (additional remarks) |
Free format text: TEILANMELDUNG 90122614.2 EINGEREICHT AM 30/11/84. |
|
| REF | Corresponds to: |
Ref document number: 3485658 Country of ref document: DE Date of ref document: 19920521 |
|
| ITF | It: translation for a ep patent filed | ||
| GBT | Gb: translation of ep patent filed (gb section 77(6)(a)/1977) | ||
| RAP2 | Party data changed (patent owner data changed or rights of a patent transferred) |
Owner name: JOZEFOWICZ, JACQUELINE Owner name: FOUGNOT, CHRISTINE Owner name: JOZEFOWICZ, MARCEL |
|
| PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PUE Owner name: MARCEL JOZEFOWICZ |
|
| 26N | No opposition filed | ||
| NLT2 | Nl: modifications (of names), taken from the european patent patent bulletin |
Owner name: MARCEL JOZEFOWICZ TE LAMORLAYE, CHRISTINE FOUGNOT |
|
| EPTA | Lu: last paid annual fee | ||
| EAL | Se: european patent in force in sweden |
Ref document number: 84402466.1 |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: IF02 |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: TP Ref country code: FR Ref legal event code: CL |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20030627 Year of fee payment: 20 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20031030 Year of fee payment: 20 Ref country code: CH Payment date: 20031030 Year of fee payment: 20 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 20031031 Year of fee payment: 20 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20031103 Year of fee payment: 20 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 20031105 Year of fee payment: 20 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20031125 Year of fee payment: 20 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20031209 Year of fee payment: 20 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20040126 Year of fee payment: 20 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20041129 Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20041129 Ref country code: CH Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20041129 |
|
| BE20 | Be: patent expired |
Owner name: S.A. *CHOAY Effective date: 20041130 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20041130 Ref country code: LU Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20041130 Ref country code: AT Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20041130 |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: PE20 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
| EUG | Se: european patent has lapsed | ||
| NLV7 | Nl: ceased due to reaching the maximum lifetime of a patent |
Effective date: 20041130 |
|
| EUG | Se: european patent has lapsed |